Results 81 to 90 of about 516,620 (290)

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. [PDF]

Front Immunol, 2022
Hambach J, Mann AM, Bannas P, Koch-Nolte F.   +3 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

What are bispecific antibodies?

Introduction In recent decades therapeutic antibodies have become recognised as an effective form of systemic therapy in the management of many paediatric conditions from Crohn’s disease to asthma and cancer.1–3 Bispecific antibodies are a growing area ...
Crombie, Katherine, Potluri, Sandeep, Apps, John R   +2 more
core   +1 more source

Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review) [PDF]

, 2019
Therapeutic monoclonal antibodies have long been an effective tool deployed by physicians of different specialties, particularly by oncologists. Bispecific antibodies opened up new horizons in the treatment of cancer as they allow to involve a patient’s ...
O.N. Solopova, Vsevolod Andreevich Misyurin, O. N. Solopova   +2 more
core   +1 more source

Next‐Generation Glutamine Synthetase Expression Vector for Therapeutic Protein Manufacturing Using CHO Cells

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The glutamine synthetase expression system is widely used for therapeutic protein biomanufacturing in Chinese hamster ovary (CHO) cells. Here, we present the design of an enhanced glutamine synthetase vector for generating CHOK1SV GS‐KO stable pools that produce recombinant proteins at multigram‐per‐liter levels. We first developed a synthetic
Yusuf B. Johari, Sophie J. Wensley, Malak A. Ammar, Avinash Srivastava, Changhavi Ragurajan, Jenish Patel, Natalie C. Elliott, Alice C. Hodgson‐Casson, Mariano Olivera Fedi, Michael Anbar, Peter M. O'Callaghan, Bernie Sweeney   +11 more
wiley   +1 more source

Screening of bispecific antibodies during single cell cloning of recombinant Chinese hamster ovary cell lines to improve titer and product quality

Biotechnology Progress, EarlyView.
Abstract Development of therapeutic bispecific antibodies (BsAbs) poses significant manufacturability challenges associated with correct chain pairing and an increased diversity of impurities. Here we address this with a product quality assessment during cell line development (CLD), forgoing the need for genetic characterization during cell line ...
Molly Robinson, Jessica Willmott, Holly Corrigall, Daniela Lega, Joseph Stirling, Vithiya Vimalraj, Mitul Patel, Robyn Emmins   +7 more
wiley   +1 more source

Development and application of a mechanistic model for protein A resolution of a bispecific antibody for process characterization and optimization

Biotechnology Progress, EarlyView.
Abstract Regeneron's bispecific technology, based on a fully human IgG antibody construct, consists of two distinct heavy chains and a common light chain co‐expressed in a single cell. The co‐expression of the two distinct heavy chains, one of which contains a dipeptide substitution that ablates Protein A binding, leads to the formation of three ...
Samantha Wadsworth, James Reilly, John Mattila, Christopher Cowan, Hanne Bak   +4 more
wiley   +1 more source

Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies

, 2014
The development and approval of antibody-based therapeutics have progressed rapidly over the past decade. However, poor blood-brain barrier (BBB) permeability hinders the progress of antibody therapies for conditions in which the target is located in the
Graham K. Farrington, Haqqani, Arslan S., Arsalan S. Haqqani, Kemmerich, Kristen, Kristin Kemmerich, Farrington, Graham K., Danica Stanimirovic, Stanimirovic, Danica   +7 more
core   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source